Profil bibliographique

Moshe Levy

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

338Publications signalées

8257Citations signalées

3Affiliations récentes

Institutions déclarées

Hebrew University of Jerusalem Texas Oncology Baylor Scott & White Health

Domaines associés

Financial Markets and Investment StrategiesChronic Lymphocytic Leukemia ResearchMultiple Myeloma Research and TreatmentsChronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research

Publications récentes

2026 articleOpenAlex

POSTER: CLL-560: How Many Lines of Therapy Do Patients With CLL/SLL Receive in Routine Clinical Practice in the United States? Real-World Evidence From the Targeted Therapy Era

Deborah M Stephens, Moshe Levy, Naleen Raj Bhandari, Tomoko Sugihara et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

2026 articleOpenAlex

POSTER: IBCL-740: Anchored Matching-Adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 vs inMIND

Kim Linton, Moshe Levy, Dai Maruyama, Abel Costa et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

2026 conference-abstractOpenAlex

CLL-560: How Many Lines of Therapy Do Patients With CLL/SLL Receive in Routine Clinical Practice in the United States? Real‐World Evidence From the Targeted Therapy Era

Deborah M Stephens, Moshe Levy, Naleen Raj Bhandari, Tomoko Sugihara et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

2026 articleOpenAlex

IBCL-740: Anchored Matching-Adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 vs inMIND

Kim Linton, Moshe Levy, Dai Maruyama, Abel Costa et autres

0 citationsClinical Lymphoma Myeloma & Leukemia

Accès ouvert 2026 articleOpenAlex

Mutual Fund Selection When Borrowing Is Restricted: On the Virtues of the Generalized Geometric Mean

Moshe Levy

0 citationsFinancial Analysts Journal

2025 conference-abstractOpenAlex

Zanubrutinib is well tolerated and effective in acalabrutinib-intolerant patients with B-cell malignancies: A long-term follow-up

Mazyar Shadman, Ian W. Flinn, Moshe Levy, Steven W. Papish et autres

0 citationsBlood

2025 conference-abstractOpenAlex

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (TKI)

Jörge E. Cortes, Ehab Atallah, David Andorsky, Marlise R. Luskin et autres

0 citationsBlood

2025 conference-abstractOpenAlex

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts)

Moshe Levy, David Andorsky, CelesteAnn Bremer, Joshua F. Zeidner et autres

0 citationsBlood

Accès ouvert 2025 erratumOpenAlex

Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

Sheri Skerget, Daniel Peñaherrera, Ajai Chari, Sundar Jagannath et autres

0 citationsNature Genetics

Accès ouvert 2025 articleOpenAlex

Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Barry Paul, Jiří Minařík, Francesca Cottini, Cristina Gasparetto et autres

2 citationseJHaem

2025 conference-abstractOpenAlex

Efficacy and safety of asciminib (ASC) in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI): Interim analysis (IA) of the phase 2 ASC2ESCALATE trial.

David Andorsky, Marlise R. Luskin, Srinivas K. Tantravahi, Koji Sasaki et autres

0 citationsJournal of Clinical Oncology

2025 articleOpenAlex

The cost of uninformed market timing

Moshe Levy

0 citationsEuropean Journal of Operational Research

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.